A cancer drug that cannot be manufactured in a factory, because it is made out of the patient

Almost every medicine you have taken was made in a factory, in a batch, months before you needed it. CAR-T therapy cannot work that way. There is no vial on a shelf, because the active ingredient is the patient's own white blood cells — collected, genetically rewritten in a laboratory over a couple of weeks, grown into the hundreds of millions, and infused back into the same person they came from. One dose, one patient, no substitutions. Everything remarkable about this treatment and everything difficult about it come from that single fact.

Why the immune system misses cancer

T cells are the immune system's assassins, and they are good at it. The problem is how they are wired to look.

A T cell does not inspect a cell's surface directly. It waits for cells to display fragments of their internal proteins on a surface molecule called MHC — a continuous self-report, in effect, of what each cell has been making. A virus-infected cell displays viral fragments and gets killed. That system works beautifully against pathogens and badly against cancer, for two reasons. A tumour cell is a corrupted version of you, so most of what it displays is genuinely self and provokes nothing. And tumours are under constant selection: any clone that reduces its MHC display becomes harder to see, so that is exactly the clone that survives and grows.

The result is a cancer that is visible to the eye of a pathologist and invisible to a T cell. Checkpoint inhibitors, the other great immunotherapy of the last decade, work by releasing the brakes on T cells that can still see the tumour. CAR-T solves a different problem: what to do when they cannot see it at all.

A receptor stitched together from parts

The engineering answer is to give the T cell a completely new pair of eyes — a chimeric antigen receptor, chimeric because it is assembled from pieces of different proteins that never met in nature.

The outward-facing end is derived from an antibody: the small fragment that does the actual gripping, chosen to bind a protein sitting on the cancer cell's surface. This is the crucial substitution. Antibodies read surfaces directly and have no interest in MHC, so a T cell carrying one can recognise a tumour that has stopped presenting anything at all.

That binding fragment is fused through the cell membrane to the signalling machinery a T cell normally uses when its natural receptor is triggered — the activation domain, plus a co-stimulatory domain that supplies the second signal T cells require to commit, proliferate and persist rather than shrug and shut down. Getting that second domain right is much of the difference between the early designs that did nothing and the generation that started curing people.

The commonest target in practice is CD19, a protein on the surface of B cells. It is not cancer-specific — it is on healthy B cells too — which sounds like a fatal flaw and turns out to be a survivable one, for a reason we will come to.

How a single dose is built

The manufacturing route is the reason this therapy costs what it does.

Blood is drawn and passed through a machine that separates out white cells and returns the rest — leukapheresis, a few hours in a chair. The T cells are isolated and activated, then the CAR gene is delivered into them, usually by a disabled lentivirus engineered to carry the construct and nothing else. The modified cells are then grown for one to two weeks until there are enough, tested extensively for identity, potency and sterility, frozen, and shipped back to the hospital.

Meanwhile the patient receives a short course of lymphodepleting chemotherapy — deliberately clearing space and growth signals so the incoming cells are not out-competed by the immune system already present. Then the dose is infused, usually in a few minutes.

The interval from collection to infusion is called vein-to-vein time, and for a patient with fast-moving disease it is the whole ballgame. Every step is bespoke: a dedicated cleanroom suite occupied by one person's cells, a batch of clinical-grade viral vector, a full quality-control panel, and a cryogenic chain — all for a single treatment that cannot be pooled, stockpiled or reused if that patient deteriorates first.

This is not a drug that happens to be expensive. It is a manufacturing process run once, for one person, with hospital-grade quality control on a batch size of one.

What it cures, and what it does not

Against B-cell cancers the results changed what oncologists thought was possible. In relapsed or refractory B-cell acute lymphoblastic leukaemia and several lymphomas — patients who had exhausted chemotherapy and transplant — a single infusion produces complete remissions in a substantial fraction, and a meaningful number of those remissions have now held for years. The first approval came in 2017; myeloma followed with a different target, BCMA.

The reason it works here is that B-cell cancers offered something rare: a clean, uniform surface marker present on essentially every malignant cell, whose healthy counterpart the body can live without. Killing all the CD19-positive cells removes the patient's B cells too — B-cell aplasia — and that is managed, indefinitely if necessary, with immunoglobulin replacement. A tolerable trade, and a very unusual one.

Solid tumours have refused to follow, and the obstacles are structural rather than a matter of tuning. There is rarely an antigen that is on all the tumour and on no essential tissue — and being wrong here is dangerous, because a CAR that binds a protein on healthy lung or liver will attack it with the same efficiency. The cells must then physically infiltrate a dense mass rather than meet their targets floating in blood and marrow. And once inside, they enter a microenvironment built to suppress them: low oxygen, hostile metabolites, and resident cells actively switching off the immune response. Trials continue in glioblastoma, sarcoma and elsewhere; honest summaries still describe them as early.

The two ways it goes wrong

CAR-T's toxicities are not incidental. They are the consequence of the therapy working.

Cytokine release syndrome is a storm of inflammatory signalling from millions of newly activated T cells killing at once — high fever, plunging blood pressure, organ strain, usually within days. It is now well characterised and largely manageable, chiefly by blocking the IL-6 pathway, sometimes with steroids. Its arrival is, awkwardly, a sign the cells are alive and doing their job.

Neurotoxicity, formally ICANS, is stranger and less understood: confusion, tremor, difficulty writing, sometimes seizures, usually reversible with prompt treatment. Both syndromes are why this therapy is delivered only at accredited centres with intensive care on hand, and why the vein-to-vein logistics matter as much as the biology.

There is also a long-term question the field takes seriously: because the CAR gene integrates into the T cell's own genome, regulators added a warning in 2024 about rare secondary T-cell cancers reported after treatment. The events are rare and the patients involved were heavily pre-treated, but it is an active area of surveillance rather than a closed question.

Why the price came down in India

For years the sticker price was the barrier — the approved Western products run to figures that only insurance systems can absorb, and for most Indian patients that placed the therapy outside reality regardless of eligibility.

That changed with NexCAR19, developed by ImmunoACT with IIT Bombay and Tata Memorial Centre and approved by the Indian regulator in 2023 as the country's first indigenous CAR-T product. It was built end to end domestically — vector, cell processing, quality systems — and priced at a small fraction of the imported equivalents, bringing a therapy that had been effectively unavailable into the range of a large hospital's oncology programme. It is a genuine demonstration that the cost of cell therapy is dominated by manufacturing and supply chain rather than by anything inherent in the biology.

The direction of travel is the same everywhere: allogeneic products made in advance from healthy donor cells and edited so they are not rejected, which would turn a bespoke process into an off-the-shelf one; and, further out, generating the CAR inside the patient's own body using targeted delivery, removing the factory step entirely.

Why it matters for students and researchers

CAR-T is what a fully integrated bioengineering problem looks like. A single therapy requires protein engineering to design the receptor, viral vectorology to deliver the gene, cell-culture process engineering to expand the product reliably, cryobiology and logistics to move it, clinical protocols to manage predictable toxicity, and regulatory science for a product where every batch is unique.

That breadth is the opportunity. India has the patient population, the clinical infrastructure and now a proven domestic precedent, and the bottleneck is people who understand manufacturing biology rather than only the molecular story — vector production, closed-system cell processing, potency assays, cold chain. For students in biotechnology and bioengineering, the interesting frontier here is not that immune cells can be reprogrammed. It is that doing it reproducibly, safely and affordably is still an unsolved engineering problem, and a solvable one.

Frequently asked questions

What is CAR-T cell therapy?

It is a treatment in which a patient's own T cells are collected, genetically modified in a laboratory to carry a chimeric antigen receptor that recognises a protein on their cancer cells, grown in large numbers, and infused back so they can find and kill the tumour.

How is it different from chemotherapy?

Chemotherapy is a drug that kills dividing cells broadly. CAR-T is a living therapy: the infused cells multiply inside the body, hunt a specific surface target, and can persist for months or years, which is why a single infusion can produce a lasting remission.

Why does CAR-T not work well for solid tumours?

Solid tumours rarely have a surface marker present on all cancer cells and absent from vital tissue, the engineered cells struggle to physically penetrate a dense mass, and the tumour microenvironment actively suppresses immune activity once they get in.

What are the main side effects?

Cytokine release syndrome — fever and low blood pressure from mass immune activation — and neurotoxicity known as ICANS, causing confusion or seizures. Both are usually reversible when treated promptly, which is why the therapy is given only at specialised centres.

Is CAR-T available in India?

Yes. NexCAR19, developed by ImmunoACT with IIT Bombay and Tata Memorial Centre, was approved by the Indian regulator in 2023 as the first indigenous CAR-T therapy, at a small fraction of the cost of imported products.